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Identity 
Other names: CT63, OXTES1 
HGNC (Hugo): PASD1 
Location: Xq28 
Note: PASD1 gene encodes a protein thought to be a 
transcription factor (Entrez Gene). In normal 
tissues expression is restricted to immunologically 
protected sites (which lack MHC class I expression) 
such as the testes, however the demonstration of 
expression in haematological malignancies and a 
range of solid tumour cell lines indicates it is a 
cancer-testis antigen (Liggins et al., 2004a; Liggins 
et al., 2004b; Guinn et al., 2005; Cooper et al., 2006; 
Sahota et al., 2006). 
DNA/RNA 
Description 
113205 bases. 
Transcription 
The PASD1 gene is alternatively spliced into two 
transcripts named PASD1_v1 and PASD1_v2. 
PASD1_v2 lacks intron 14 and a retained stop signal 
(Liggins et al., 2004a).  
Differential splicing is predicted to create additional 
novel PASD1 isoforms as a protein smaller than 
PASD1_v1 and PASD1_v2 has been detected in OCi-
Ly3 and FEPD cells (Cooper et al., 2006). 
Transcripts found in 33% (4 of 12) acute myeloid 
leukaemia patients, 1 of 6 chronic myeloid leukaemia 
patients and 4 of 16 cell lines (Guinn et al., 2005). 
Transcripts have been found in 5 of 11 multiple 
myeloma cell lines including THIEL and RPMI8226, 
and 14 of 16 primary multiple myeloma samples 
(Sahota et al., 2006), 22 of 25 B- and T-cell 
malignancy cell lines (Liggins et al., 2010). 
 
Structure of the PASD1 gene from which (A) PASD1_v1 and (B) PASD1_v2 and transcribed. Lines indicate introns, boxes exons, 
the filled box the retained intron in PASD1_v1, "atg" the predicted start site and "tga" the predicted stop site (Liggins et al., 2004a). 
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Schematic illustration of the functional domains within the PASD1 protein. PASD1a protein translated from PASD1_v1 (A) and 
PASD1b translated from PASD1_v2 (B) are shown (Liggins et al., 2004a). 
 
Protein 
Description 
Contains a Per Arnt Sim (PAS) domains in the N-
terminal regions between aa 32-94 and aa 41-137 
(Liggins et al., 2004a). 
Expression 
Expression highest in G361 (melanoma) and SW480 
(colorectal adenocarcinoma) cell lines of a panel of 
nine tested.  
Expression in 25 of 68 solid tumours on matched 
tumour/normal arrays (Liggins et al., 2004a). 
Expression restricted in normal tissues, placenta and 
testes, not detected in panel of normal tissue cDNAs.  
Expression also found in K562, Jurkats (T-cell 
leukaemia), Hn5 (head and neck cancer) and highest in 
H1299 (lung cancer) cell lines by real-time PCR 
(Guinn et al., 2005). 
Of the normal tissues expression was restricted to testes 
and not found in a range of normal tissues including 
brain, liver, kidney, placenta, breast, uterus or ovary 
(Guinn et al., 2005; Cooper et al., 2006). 
Expression of PASD1 was demonstrated in OCI-Ly3 
(non-germinal centre diffuse large B-cell lymphoma-
derived cells), FEDP (ALK-negative anaplastic large-
cell lymphoma), Granta519 (mantle cell lymphoma) 
KM-H2 (Hodgkin's lymphoma), K562 (chronic 
myeloid leukaemia) and Thiel (multiple myeloma) cell 
lines and 21/51 diffuse large B-cell lymphoma patients, 
4/9 mantle cell lymphoma, 4/15 follicular lymphomas  
 
and a range of other tumour cells from patients with 
haematological malignancies (Cooper et al., 2006). 
Expression has been detected in the multiple myeloma 
cell lines THIEL and RPMI8226, in the testis and in 
two of four primary multiple myeloma tumour samples 
(Sahota et al., 2006). 
Not found in 78 basal cell carcinoma by real-time PCR 
(Ghafouri-Fard et al., 2010). 
Localisation 
In normal tissues expression was only found in the 
nuclei of a subpopulation of spermatogonia near the 
basal membrane in the testicular tubules (Cooper et al., 
2006). 
PASD1 protein has shown variable expression. In OCI-
Ly3 cells, PASD1 expression was found on the 
membrane and in the cytoplasm.  
Nuclear staining of KM-H2, K562 and Thiel cells, 
nuclear and cytoplasmic staining of Granta519 (Cooper 
et al., 2006). 
Function 
The protein is thought to be a transcription factor 
(Entrez Gene). No role in human cell cycle (Denniss 
and Guinn, unpublished data).  
Detected by virtue of patient humoral responses 
(Liggins et al., 2004b; Guinn et al., 2005), it has shown 
to stimulate CD3+ (Guinn et al., 2005), CD4+ (Ait-
Tahar et al., 2011) and CD8+ T cell responses (Ait-
Tahar et al., 2009; Joseph-Pietras et al., 2010; 
Hardwick et al., submitted) in mixed lymphocyte 
reactions (MLR) and cytotoxic T lymphocyte (CTL) 
assays. 
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Homology 
PASD1 has been identified in cow, chicken and mouse 
where it is known as GM1141 (Entrez Gene). 
Similarity to the CLOCK gene in mice which is 
essential for circadian behaviour. 
Implicated in 
Diffuse large B-cell lymphoma (DLBCL) 
Note 
DLBCL is the most common type of non-Hodgkins 
lymphoma and is caused by malignant mature B 
lymphocytes. Around half the number of patients 
diagnosed die from the disease (Alizadeh et al., 2000). 
Using gene expression patterns two types of DLBCL 
have been identified, 'germinal centre B-like DLBCL' 
and 'activated B-like DLBCL' (Alizadeh et al., 2000). 
PASD1 antigen is recognized by DLBCL patient sera 
(Liggins et al., 2004b) 
Prognosis 
Germinal centre markers CD10, BCL6 and non-
germinal centre marker MUM1 have been used to 
identify prognosis and survival of DLBCL patients. 
CD10 or BCL6 expression predicted better overall 
survival but MUM1 expression suggested worse overall 
survival (Hans et al., 2004). Germinal centre type 
associated with good prognosis. Patients with non-
germinal centre type showed serum reactivity with 
PASD1, and PASD1_v2 expression was restricted to 
non-germinal cell lines (Liggins et al., 2004a). 
Acute myeloid leukaemia (AML) and 
chronic myeloid leukaemia (CML) 
Note 
PASD1 was recognized by 35% of AML, 6% of CML 
and 10% of DLBCL sera but not the normal donor sera. 
Expression was found in 33% (4 of 12) AML and 17% 
(1 of 6) chronic myeloid leukaemia patient samples 
(Guinn et al., 2005) by RT-PCR and confirmed by RQ-
PCR. 
Multiple myeloma 
Note 
Cancer of the plasma cells in bone marrow. PASD1 
expression has been seen in multiple myeloma cell 
lines by RT-PCR and in primary multiple myeloma 
samples by Q-PCR at presentation and previously 
treated cases (Sahota et al., 2006). 
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